

### **Comprehensive Update:**

### Buy

### Target price: 7214 HUF

Industry:	Construction Materials
Country:	Hungary
ISIN:	HU0000093943
Reuters:	
Bloomberg:	MASTERPL:LN
Website:	www.masterplastgroup.com

Last price in HUF:		3925 HUF
	High	Low
Price 52 W.	4790	2700
Market cap. (HUF '000)		57,310,000.00
Number of shares (thousands)		14,601,279.00

Shareholders	
Dávid Tibor	31.15%
Balázs Ács	26.55%
SOH Kft. & LPH Kft. Jointly	5.47%
Róbert Nádasi	0.72%
Minority shareholders	36.1%

#### Performance

4 weeks	3.02%
12 weeks	-0.64%
52 weeks	-15.70%
5 years	707.21%

Dividend		
	in EUR	in %
2015	0.00	0.00%
2016	0.07	1.98%
2017	0.09	3.54%
2018	0.04	1.98%
2019	0.10	5.27%
2020	0.00	0.00%
2021	0.12	2.22%



# DR. KALLIWODA RESEARCH on Bloomberg

Page: KALL Analyst:

Dr. Norbert Kalliwoda E-Mail: nk@kalliwoda.com Phone: +49 69 97 20 58 53 www.kalliwoda.com

# **Masterplast Nyrt.:**

### Strong position in the thermal insulation industry

- Masterplast has a strong position in the thermal insulation industry, primarily in the renovation sector. High energy prices will lead to additional company growth
- In Q2 2022, Masterplast achieved record sales of EUR 57,597,000, mainly backed by its thermal insulation business.
- Business segments of 'roofing foils and accessories, 'building industrial accessories', and 'industrial applications' contributed negatively to sales.
- Masterplast recorded strong sales growth from Italy, Romania, Slovakia, and Serbia. Moderate sales growth was recorded in Hungary, Croatia, Poland and North Macedonia, while a decrease in sales growth was recorded in Germany and Ukraine.
- From a macro-economic perspective, the unstable conflict situation in Ukraine, rising energy prices and high inflation threaten operations in Masterplast in its jurisdictions of operations.
- Based on our DCF-Model we increase our Target Price from HUF 6152 to HUF 7214.

#### **Key Figures**

in '000 EUR	2019	2020	2021	2022E	2023E	2024E	2025E
Net sales	107,104.24	122,672.71	191,488.70	216,382.23	247,757.65	278,727.36	306,600.10
EBITDA	7,327.17	11,076.38	22,830.76	24,366.73	27,487.64	35,900.06	40,653.04
EBIT	5,242.12	8,203.10	18,275.23	19,389.94	21,789.22	29,489.33	33,601.24
Net income	4,762.92	6,438.98	16,070.37	14,374.38	16,548.97	23,062.52	26,742.91
EPS	0.32	0.32	1.20	0.92	1.06	1.48	1.71
BVPS	2.46	2.78	3.65	4.96	5.30	6.05	6.51
RoE	14.61%	17.46%	33.23%	21.85%	23.54%	28.78%	31.00%
EBIT margin	4.90%	6.69%	9.54%	8.96%	8.79%	10.58%	10.96%
P/E	17.57	62.70	16.77	21.77	18.91	13.57	11.70
P/BVPS	8.16x	7.21x	5.50x	4.04x	3.78x	3.32x	3.08x
EV/EBITDA	42.46x	29.84x	16.77x	15.54x	14.14x	10.98x	9.92x

Source: Dr. Kalliwoda Research GmbH © 2022 & Masterplast Nyrt.

# Content

1.	Q2 Report 2022	3
2.	Company Profile	7
3.	SWOT Analysis	9
4.	Valuation	10
5.	Profit & Loss	12
6.	Balance Sheet	12
7.	Financial Ratios	13
8.	Contacts	14
9.	Disclaimer: Material information, disclosures and disclaimers	16

### 1. Q2 Report 2022

### 1. Summary

Masterplast's sales of EUR 57,597,000 in Q2 exceeded the record base, primarily backed by the increase in turnover from thermal insulation as opposed to solid sales of medical protective clothing, which drove last year's revenue. Both the company's increased production output and the improved efficiency in manufacturing contributed significantly to its profit generation, which outperformed H1 2021 base healthcare sales, including higher gross margin volumes than the construction segment. As a result of the expanded production, the company increased personnel and material costs. The H1 2022 EBITDA noted an increase of 6% to EUR 13,634,000 compared to the H1 2021, while Q2 profit-after-tax increased by 30% to EUR 8,258,000 and the total H1 2022 profit-after-tax was EUR 11,477,000, which is almost 70% of the forecasted annual profit. The intensifying European energy independence goals and high energy prices project a positive industry trend for the thermal insulation industry, primarily in the renovation sector. That, combined with Masterplast's strong production background, stable supply chain, high inventory level, and soon-to-be-completed investments, demonstrate a strong foundation for its further growth to surpass its profits-after-tax forecast for 2022, provided that the currency markets remain favorable for the company.

	Financial Data	Q2 2022 - Master	plast Nyrt.	
Data in 1000 EUR	Q2 2022	Q2 2021	H1 2022	H1 2021
Sales Revenue	57,597	57,138	109,107	95,418
EBITDA	8,400	8,505	13,634	12,877
EBITDA Ratio	14.60%	14.90%	12.50%	13.50%
Profit/Loss after Taxes	8,258	6,349	11,477	9,147
Net Income Ratio	14.30%	11,1%	10.50%	9.60%

Increasing supply difficulties and rising prices due to the Russian-Ukrainian war, and rising inflation had a mixed effect on construction demand in the company's overall markets. The construction industry's performance witnessed an increase in the Hungarian, Italian and Croatian markets, while an unfavourable industry trend was demonstrated in Romania, Germany, Slovakia, Poland and Serbia. In its other markets, Higher prices and volumes in the construction segment drove Q2 2022 sales to EUR 57,597,000, a 1% increase compared to H1 2021. In terms of the sales of Q2 2022, the thermal insulation systems product group, representing roughly over half of the total group revenue, expanded by 47%. The revenue from the dry construction system product group rose by 20%, and the turnover of heat-, sound- and water insulation materials by 26%. The sales of roofing foils and accessories experienced a slight decline of 19%, while the sales of building industry accessories also experienced a moderate decrease of 6%.

Meanwhile, the decreasing health industry sales drove down the turnover of the industrial applications product group by a whopping 58%. Sales from the Italian and Croatian markets sharply increased by 82% and 45%. Sales also improved in the export markets Romania (14%), Serbia (15%), Croatia (4%), and North Macedonia (1%). In the Hungarian market, overall turnover decreased by 8% compared to the base period, where insulation and construction industry sales increased significantly (45%), while the turnover of healthcare products decreased compared to last year's excellent base. Sales declined in Germany (-5%) and Poland (-11%), while sales in Ukraine fell by 47% in Q2. On the bright side, however, the Company's Ukrainian market

sales have started to demonstrate a catching-up trend. The Gross margin in Q2 2022 was almost at the level of the base period amount, thanks to the stable performance of the construction industry segment and the further rise of self-produced products. Despite the significant decrease in the share of the healthcare segment with higher profitability, output at the Serbian EPS, mesh edge and fibreglass mesh factory increased compared to last year. However, the foam factory in Kal produced below its base. Emissions from the Aschersleben plant decreased compared to the previous year's period. At the Sarszentmihaly production site for fleece and sanitary raw materials, trial production and optimization of production capacity continued and terminated with success. Raw material supply disruptions, which have resurfaced due to the war situation, have been successfully managed in all the company's factories, ensuring continuity of production. Considering the change in the self-manufactured inventories, the cost of materials and services also increased by 1%, in line with the turnover growth in Q2 2022, compared to the prior base year. Due to the new factory units established in Hungary, The personnel expenses of the company increased in Q2 2022, while the higher number of employees in Serbia and the salary increase were in line with market trends. The Group had 1551 employees at the end of June 2022, compared to the staff level of 1207 last year.

The increased depreciation amount was driven by the established new CAPEX investment in the Hungarian site. On the other operating income line, the company recorded a profit of EUR 1,005,000 as opposed to a loss of 300,000 last year. The Group's EBITDA in Q2 2022 was also up by 20% to EUR 8,400,000. After factoring in depreciation, the operating profit in the fourth quarter amounted to EUR 7,047,000, compared to last year's value of EUR 7,388,000. Due to bond issues in Q3 2021, The company's interest expenses increased, while other financial operations resulted in a higher profit in Q2 2022 compared to the base period due to favourable exchange rate effects for the company.

Sa	ales by main prod	uct groups Q2 202	2 - Masterplast N	rt.		
Data in 1000 EUR	Q2 2022	Q2 2021	Change	H1 2022	H1 2021	Change
Thermal insulation system	30 930	21,045	47%	56,808	34,840	63%
Roofing foils and accessories	6,662	8,255	-19%	14,156	14,257	-1%
Dry construction systems	5,299	4,418	20%	11,010	8,606	28%
Heat, sound and water insulation materials	5,912	4,697	26%	10,185	7,952	28%
Building industr accessories	1,563	1,658	-6%	3,016	2,856	6%
Industrial applications	7,231	17,065	-58%	13,932	26,907	-48%
Total Sales Revenue	57,597	57,597	1%	109,107	95,418	14%
Contribution of product groups in percentag	ge to the total sale:	s revenue				
Thermal insulation system	54%	36%	-	52%	37%	-
Roofing foils and accessories	12%	15%	-	13%	15%	-
Dry construction systems	9%	8%	-	10%	9%	-
Heat, sound and water insulation materials	10%	8%	-	9%	8%	-
Building industr accessories	3%	3%	-	3%	3%	-
Industrial applications	12%	30%	-	13%	28%	-
Total Sales Revenue	100%	100%	-	100%	100%	-

#### 2. Business Prospects

Amongst the macroeconomic factors impacting the business activities and its markets are the high inflation and the rising interest rates due to the tightening of monetary policy by the central banks. And while the new construction market is gradually slowing down, Experts expect a strong recovery in the renovation market. In light of events in Ukraine and the resulting energy crisis, energy modernization of buildings has become essential in dealing with the situation, making the role of insulation indispensable. The guidelines in the 'REPowerEU' programme foresee the emergence of solid building energy support programmes. This could ensure a long-term increase in demand for insulation materials.

The third phase of the fibreglass mesh production development was recently completed during the second quarter and is already fueling the company's growth. The new plant under the XPS insulation material production development is scheduled to start production next year. The company has launched investments in the production of EPS-based insulation materials in Italy and at its Kal site, where production is also expected to start early next year. The production of health textiles and finished healthcare products at the company's main site is scheduled to be productive from the year's second half, whereas the product portfolio is undergoing quality testing with the established customer base. Supply chain disruptions caused by the Russian-Ukrainian war, the energy crisis and the epidemic further drive up raw material costs and result in supply difficulties for economic operators. Masterplast is working with high stocks of raw materials to mitigate these difficulties. Its inventory and diversified supplier portfolio ensure business continuity and high service levels. The Group has also resumed operations in Ukraine in non-war-affected areas. The potential impact on the Group's limited profitability from operations is considered marginal, given the proportion of the territory involved at the Group level. In the medium to long term, the business potential for Masterplast, as a long- and well-established building- and insulation materials producer in the Ukrainian market, may offset the loss of revenues during the war period.

The stable supply chain, the manufacturing and development investments made and underway, and the solid financial backing coupled with the agile organizational culture provide a solid basis for the company's further and sustainable growth into the future. In light of the first half-year results, if the company's favourable currency environment holds up into the year's second half, the annual profit after tax could exceed the yearly forecast of EUR 16.5 million.

#### 3. Presentation of the external economic and industrial environment

The sale of the construction and accessories products is mainly related to the new-buildings market, while the sales of insulation-related materials (primarily heat insulation) depend on both the new building and home renovation markets. The effects of the reshaping market conditions from the Ukraine war have stimulated industry demand in several markets through purchases made earlier than planned in the quarter under review. At the same time, the construction and insulation markets are being boosted by government subsidies and programmes to support climate protection and energy efficiency targets and climate protection.

Hungary - In the Hungarian market, available statistics show an increase in construction output and the number of new contracts signed in the first months of 2022 compared to last year. Favourable industry trends prevailed in the construction sector during the quarter thanks to government support through the family support home creation programme, home renovation support for families with young children, and preferential loans provided by the national bank under the 'Green Home programme' continuing to keep residential investment up. The state is trying to mitigate the impact of soaring energy prices by regulating prices and making them more affordable for the public.

Romania - construction output has been on a downward trend due to macroeconomic effects. The significant increase in the price of building materials, impacted by the rise in energy and primary raw material prices, is holding back the volume of work.

Serbia – Although the GDP and the number of building permits issued increased compared to last year, construction output declined. Inflation, here, too, has a negative impact. The state is working on mitigating the adverse effects of the energy crisis on economic activity through various measures, such as limiting the increase in electricity prices, correcting the price of oil derivatives, gas transportation agreements, and the construction of storage facilities.

Ukraine - The prevailing war since Q1 2022 has put the economy, including the construction industry, in a precarious position for the foreseeable future, with Estimates on the country's economy pointing towards Ukraine's GDP falling by 35-50% within 2022. Construction indicators show a decline of more than 70%, while construction costs have risen by 20%, bringing the primary real estate market to a standstill. It is expected that emergency repairs, demolitions and construction of temporary structures are likely to become the leading construction activity soon.

Germany - The hope of a strong recovery in Germany was crippled by the Russian-Ukrainian conflict, with GDP growth forecasts of only 1.6% in 2022. The coronavirus epidemic appeared to have lost its hold in the second quarter of 2022. Although services have recovered since the spring, the war has prolonged problems in global supply chains, increasing energy and freight costs and thus diminishing the purchasing power. While this is deteriorating among large companies, medium-sized companies reported an overall stable business environment in June. But business expectations for the second half of 2022 are increasingly pessimistic in light of material shortages, rising construction prices, shorter working hours and the threat of Russian gas supply disruptions. The German construction industry is expected to grow from 0 to 2% this year.

Poland - Poland made fewer housing starts this year than a year earlier. The Russian-Ukrainian conflict exacerbates rising raw material and labour prices. The fighting has also hampered the labour influx from the East and the import of some construction materials. The outlook in this region is very pessimistic for the industry, with the bankruptcy threatening many industrial players.

Slovakia - High inflation due to the current runaway energy and commodity prices and shortages have put the state and the construction industry in a challenging situation. Although many new construction projects are waiting to be completed on the market, fears of an emerging crisis are high. The construction industry could be helped by the government's green programme, currently in the tendering phase, which is expected to provide €560 million to support the renovation of 30,000, not energy-efficient old houses. Despite record inflation numbers and rising prices, H1 2022 saw the construction output and the number of permits issued and the Croatian economy as a whole growing.

Sales b	y Countries (	D2 2022 - Ma	asterplast Ny		<u> </u>	
Data in 1000 EUR	Q2 2022	Q2 2021	Change	H1 2022	H1 2021	Change
Hungary	26,143	28,362	-8%	48,104	46,290	4%
Export	5,234	4,621	13%	9,824	8,418	17%
Italy	4,393	2,414	82%	9,109	3,554	156%
Romania	4,536	3,992	14%	8,863	6,453	37%
Germany	3,690	3,883	-5%	7,737	7,807	-1%
Poland	3,768	4,220	-11%	7,656	6,966	10%
Serbia	3,926	3,413	15%	7,341	5,739	28%
Slovakia	2,813	1,934	45%	4,632	3,130	48%
Ukraine	1,412	2,670	-47%	2,539	4,143	-39%
Croatia	1,146	1,099	4%	2,273	2,037	12%
North-Macedonia	536	530	1%	1,029	880	17%
<b>Total Sales Revenue</b>	57,597	57,138	1%	109,107	95,418	14%
Contribution of product groups in percenta	ge to the tota	al sales reven	ue			
Hungary	45%	50%	-	45%	49%	-
Export	9%	8%	-	9%	9%	-
Italy	8%	4%	-	8%	4%	-
Romania	8%	7%	-	8%	7%	-
Germany	6%	7%	-	7%	8%	-
Poland	7%	7%	-	7%	7%	-
Serbia	7%	6%	-	7%	6%	-
Slovakia	5%	3%	-	4%	3%	-
Ukraine	2%	5%	-	2%	4%	-
Croatia	2%	2%	-	2%	2%	-
North-Macedonia	1%	1%	-	1%	1%	-
Total Sales Revenue	100%	100%	-	100%	100%	-

## 2. Company Profile

Masterplast Nyrt. is a young and leading European company in the industrials sector. Despite being only 24 years old, the company has managed to grow from its only subsidiary in Székesfehérvár, Hungary, to having currently other subsidiaries of the Group in 9 different countries which are: Slovakia, Romania, Croatia, Serbia, Macedonia, Ukraine, Poland, and most recently Germany. In addition to these direct subsidiaries, the Company cooperates with over 6000 partners that make up for the presence of its products in 41 countries.

### Masterplast Nyrt. History

2020	Begin of operation of manufacturing site in Aschersleben, Germany
2017	Included in the premium category of the Budapest Stock Exchange
2012	Begin of fiberglass mesh production, six years later it would become the 3rd largest producer
2011	IPO at the Budapest Stock Exchange



ਹ
€.
е
Э
ŝ
Ų.
~
<u> </u>
$\equiv$
=
₽
ξ.

2005 Begin of manufacturing activities in Kál, Hungary

1999 First international expansion to Slovakia

1997 Foundation by Dávid Tibor and Balázs Ács

Source: Masterplast Nyrt.

### 3. SWOT Analysis

#### **Strengths**

- Long-term mentality: with members of the board and management owning over 50 % of the company, minority shareholders can profit from the alignment of interests which seek sustainable growth and stability.
- Positive industry trend for the thermal insulation industry:

  The Company has a strong position and further growth is expected due to high energy prices.
- Product diversification: although having been focused on construction materials while strengthening its position, Masterplast saw the right timing to enter a new market, namely the industrial textiles for the healthcare market.
- Social competence: the company has been constantly involved in activities for the benefit of the society. Financial donations and the promotion of voluntary work are part of Masterplast's strategy, also cooperation with the local city council addressing current problems and supporting the organization of events where sustainable development is the focus
- Environmental focus: besides the strong engagement with the society and promoting welfare, Masterplast also focuses on the environmental sustainability by producing insulation products that reduce waste of energy.

#### **Opportunities**

- Intensifying European energy independence goals: positive industry trend for the thermal insulation industry.
- Digitalization: given its early participation in the development of Bauapp, it can profit from the first mover advantage by offering clients better resource management and real time tracking of the products sold.
- New markets: through the already successful entrance in the German market within the healthcare sector, Masterplast is now able to not only supply the German market but also begin targeting other markets such as the French or Benelux while serving them from the plant in Germany. This could also serve as gateway for the construction materials.
- Urbanization: housing scarcity in some markets such as the Romanian provide for a stable demand backed by government support from which Masterplast can profit.

#### Weaknesses

 Geographical diversification: despite directly bei in 10 countries through subsidiaries, most reven quarters was earned in Hungary, this represents a co exposure to domestic conditions.

#### **Threats**

- Currency: disregarding the export markets, Mas currently exposed to seven different currencies ar movements may have an impact of the performal company. Using tools such as hedging can reduce the
- **Political:** the current government headed by Viktor been controversial and at times finds itself at odds or topics with the EU. Currently the country face measures to reduce the impact of the pandemic.
- Industry trends: multifamily houses have incre popularity in recent years, these require less materia

Source: Company, Dr. Kalliwoda Research GmbH © Copyright 2022

## 4. Shareholder Structure

Masterplast Nyrt. Shareholder Structure						
Shareholders						
Dávid Tibor	31.15%					
Balázs Ács	26.55%					
SOH Kft. & LPH Kft. Jointly	5.47%					
Róbert Nádasi	0.72%					
Minority shareholders	36.37%					

Source: Masterplast Nyrt.

### 5. Valuation

To value Masterplast Nyrt., we used a traditional DCF model, which derives a 12-months target price for the stock of HUF 7213. Compared to the current market level, this corresponds to an upside of approximately 83%.

WACC assumptions	
<b>Growth assumptions</b>	
Long-term growth rate	1.1%
Equity Risk-free rate Equity risk premium Beta Equity costs	6.79% 6.7% 1.45 16.52%
Debt costs	
Debt costs (before tax)	3.30%
Tax rate on interest	16.03%
Debt costs (after tax)	2.77%
	_
Equity	27%
Debt	73%
WACC	9.78%

Source: Dr. Kalliwoda Research GmbH © 2022

Debt ratio

Fair value per share in EUR/HUF today

Fair value per share in EUR/HUF in 12 months

in EUR '000 2021 2022E 2023E 2024E  Net sales 191,488.70 216,382.23 247,757.65 278,727.36 (y-o-y change) 56.1% 13.0% 14.5% 12.5%  EBIT 18,275.23 19,389.94 21,789.22 29,489.33  EBIT 15,345.03 16,281.01 18,295.59 24,761.09  NOPLAT 15,345.03 16,281.01 18,295.59 24,761.09  + Depreciation 9,5% 9,0% 8,8% 10.6%  NOPLAT 15,345.03 16,281.01 18,295.59 24,761.09  + Depreciation 4,555.52 4,976.79 5,698.43 6,410.73  = Net operating cash flow 19,900.56 21,257.80 23,994.02 31,171.82  - Total investments (Capex and WC) 62,705.72 15,539.80 22,242.95 8,183.24  Capital expenditure 40,719.80 6,273.68 4,794.89 5,034.63  Working capital 21,985.92 9,266.11 2,551.94 3,148.61  = Free Cash Flow (FCF) 242,805.16 5,718.00 21,751.07 22,988.58  Terminal Value  Source: Dr. Kalliwoda Research GmbH © 2021  PV of FCFs in explicit period 61,528.27  PV of FCFs in explicit period 61,528.27  PV of FCFs in explicit period 61,789.43  + Investments / - Minorities 1,20  Shareholder value 266,873.84  Number of shares outstanding (thousands) 14,601.28 C26 Zelle =  WACC 9,78%  Equity costs 16.5%  Debt costs before tax 3,3%  Tax rate 16.60%	
Net sales         191,488.70         216,382.23         247,757.65         278,727.36           (y-o-y change)         56.1%         13.0%         14.5%         12.5%           EBIT         18,275.23         19,389.94         21,789.22         29,489.33           EBIT margin         9.5%         9.0%         8.8%         10.6%           NOPLAT         15,345.03         16,281.01         18,295.59         24,761.09           + Depreciation         4,555.52         4,976.79         5,698.43         6,410.73           = Net operating cash flow         19,900.56         21,257.80         23,994.02         31,171.82           - Total investments (Capex and WC)         62,705.72         15,539.80         2,242.95         8,183.24           Capital expenditure         40,719.80         6,273.68         4,794.89         5,034.63           Working capital         21,985.92         2,261.1         2,551.94         3,148.61           = Free Cash Flow (FCF)         42,805.16         5,718.00         21,751.07         22,988.58           PV of FCFs         6,713.80         15,748.00         17,374.30         17,374.30         17,374.30         17,374.30         17,374.30         17,374.30         17,374.30         17,374.30         17	
Net sales	2025E
Solution   Solution	306,600.1
EBIT margin 9.5% 9.0% 8.8% 10.6% NOPLAT 15,345.03 16,281.01 18,295.59 24,761.09 + Depreciation 4,555.52 4,976.79 5,698.43 6,410.73 19,900.56 21,257.80 23,994.02 31,171.82 - Total investments (Capex and WC) 62,705.72 15,539.80 2,242.95 8,183.24 Capital expenditure 40,719.80 6,273.68 4,794.89 5,034.63 Working capital 21,985.92 9,266.11 - 2,551.94 3,148.61 = Free Cash Flow (FCF) - 42,805.16 5,718.00 21,751.07 22,988.58 PV of FCFs - 42,805.16 5,718.00 21,751.07 22,988.58 PV of FCFs in explicit period 61,528.27 PV of terminal Period 267,133.80 Implied Enterprise value (EV) 328,662.06 Net debt 61,789.43 - Number of shares outstanding (thousands) 14,601.28 C26 Zelle = WACC 9.78% Equity costs 616.5% Debt costs before tax 13.3%	10.0%
BBIT margin   9.5%   9.0%   8.8%   10.6%   NOPLAT   15,345.03   16,281.01   18,295.59   24,761.09   19,005.60   19,005.60   21,257.80   23,994.02   31,171.82   24,000   20,200   20,	33,601.24
15,345.03   16,281.01   18,295.59   24,761.09     Depreciation	11.0%
+ Depreciation	28,213.70
= Net operating cash flow	7,051.8
- Total investments (Capex and WC) 62,705.72 15,539.80 2,242.95 8,183.24 Capital expenditure 40,719.80 6,273.68 4,794.89 5,034.63 Working capital 21,985.92 9,266.11 - 2,551.94 3,148.61 = Free Cash Flow (FCF) - 42,805.16 5,718.00 21,751.07 22,988.58 PV of FCFs - 42,805.16 5,208.46 18,047.24 17,374.30 Terminal Value Source: Dr. Kalliwoda Research GmbH © 2021 PV of FCFs in explicit period 61,528.27 PV of terminal period 267,133.80 Implied Enterprise value (EV) 328,662.06 - Net debt 61,789.43 + Investments / - Minorities 1.20 Shareholder value 266,873.84	35,265.5
Capital expenditure 40,719.80 6,273.68 4,794.89 5,034.63 Working capital 21,985.92 9,266.11 - 2,551.94 3,148.61 = Free Cash Flow (FCF) - 42,805.16 5,718.00 21,751.07 22,988.58 PV of FCFs - 42,805.16 5,208.46 18,047.24 17,374.30 Terminal Value  Source: Dr. Kalliwoda Research GmbH © 2021 PV of FCFs in explicit period 61,528.27 PV of terminal period 267,133.80 Implied Enterprise value (EV) 328,662.06 - Net debt 61,789.43 + Investments / - Minorities 1.20 Shareholder value 266,873.84  Number of shares outstanding (thousands) 14,601.28 C26 Zelle =   WACC 9.78% Equity costs 16.5% Debt costs before tax 3.3%	4,909.1
Working capital 21,985.92 9,266.11 - 2,551.94 3,148.61 = Free Cash Flow (FCF) - 42,805.16 5,718.00 21,751.07 22,988.58 PV of FCFs - 42,805.16 5,208.46 18,047.24 17,374.30 Preminal Value  Source: Dr. Kalliwoda Research GmbH © 2021 PV of terminal period 61,528.27 PV of terminal period 267,133.80 Implied Enterprise value (EV) 328,662.06 - Net debt 61,789.43 + Investments / - Minorities 1.20 Shareholder value 266,873.84  Number of shares outstanding (thousands) 14,601.28 C26 Zelle =   WACC 9.78% Equity costs 16.5% Debt costs before tax 3.3%	5,286.3
PV of FCFs	377.2
Terminal Value         Source: Dr. Kalliwoda Research GmbH © 2021         PV of FCFs in explicit period       61,528.27         PV of terminal period       267,133.80         Implied Enterprise value (EV)       328,662.06         - Net debt       61,789.43         + Investments / - Minorities       1.20         Shareholder value       266,873.84         Number of shares outstanding (thousands)       14,601.28       C26 Zelle =         WACC       9.78%         Equity costs       16.5%         Debt costs before tax       3.3%	30,356.3
Cerminal Value         Source: Dr. Kalliwoda Research GmbH © 2021         PV of FCFs in explicit period       61,528.27         PV of terminal period       267,133.80         Implied Enterprise value (EV)       328,662.06         - Net debt       61,789.43         + Investments / - Minorities       1.20         Shareholder value       266,873.84         Number of shares outstanding (thousands)       14,601.28       C26 Zelle =         WACC       9.78%         Equity costs       16.5%         Debt costs before tax       3.3%	20,898.2
PV of FCFs in explicit period 61,528.27 PV of terminal period 267,133.80  Implied Enterprise value (EV) 328,662.06 - Net debt 61,789.43 + Investments / - Minorities 1.20 Shareholder value 266,873.84  Number of shares outstanding (thousands) 14,601.28 C26 Zelle =  WACC 9.78% Equity costs 16.5% Debt costs before tax 3.3%	353,454.5
PV of terminal period 267,133.80  Implied Enterprise value (EV) 328,662.06  - Net debt 61,789.43  + Investments / - Minorities 1.20  Shareholder value 266,873.84  Number of shares outstanding (thousands) 14,601.28 C26 Zelle =  WACC 9.78%  Equity costs 16.5%  Debt costs before tax 3.3%	·
Implied Enterprise value (EV)       328,662.06         - Net debt       61,789.43         + Investments / - Minorities       1.20         Shareholder value       266,873.84         Number of shares outstanding (thousands)       14,601.28 C26 Zelle =         WACC       9.78%         Equity costs       16.5%         Debt costs before tax       3.3%	
- Net debt 61,789.43 + Investments / - Minorities 1.20   Shareholder value 266,873.84    Number of shares outstanding (thousands) 14,601.28 C26 Zelle =   WACC 9.78%   Equity costs 16.5%   Debt costs before tax 3.3%	
+ Investments / - Minorities 1.20 Shareholder value 266,873.84  Number of shares outstanding (thousands) 14,601.28 C26 Zelle =  WACC 9.78%  Equity costs 16.5% Debt costs before tax 3.3%	
Shareholder value  266,873.84  Number of shares outstanding (thousands)  14,601.28 C26 Zelle =  WACC  9.78%  Equity costs  16.5%  Debt costs before tax  3.3%	
Number of shares outstanding (thousands)  14,601.28 C26 Zelle =  WACC  9.78%  Equity costs  16.5%  Debt costs before tax  3.3%	
WACC 9.78% Equity costs 16.5% Debt costs before tax 3.3%	
Equity costs Debt costs before tax 16.5% 3.3%	
Equity costs Debt costs before tax 16.5% 3.3%	
Debt costs before tax 3.3%	
10.0%	
Debt costs after tax 2.8%	
Equity ratio 27.0%	

73.0%

18.28

20.07

6,571.10

7,213.95

Upside

80.6%

## 6. Profit & Loss

Profit and Loss Statement - Masterplast Nyrt.														
								Fiscal Year						•
all figures in '000 EUR unless otherwise indicated	·	2019		2020		2021		2022E		2023E		2024E		2025E
Revenue		107,104.24		122,672.71		191,488.70		216,382.23		247,757.65		278,727.36		306,600.10
Materials and Services Used	-	87,807.54	-	95,790.04	-	146,994.15	-	167,441.96	-	193,746.48	-	214,620.07	-	236,082.07
Gross Profit		19,296.70		26,882.67		44,494.55		48,940.27		54,011.17		64,107.29		70,518.02
Payments to personnel	-	14,026.92	-	16,196.62	-	21,394.76	-	23,106.34	-	24,723.78	-	26,454.45	-	28,306.26
Movements in self produced inventories		1,837.97		969.98		4,173.23		2,086.61		1,043.31		521.65		260.83
Other operating income (expense)		219.43	-	579.65	-	4,442.26	-	3,553.81	-	2,843.05	-	2,274.44	-	1,819.55
EBITDA		7,327.17		11,076.38		22,830.76		24,366.73		27,487.64		35,900.06		40,653.04
Depreciation, Amortization and Impairment	-	2,085.06	-	2,873.28	-	4,555.52	-	4,976.79	-	5,698.43	-	6,410.73	-	7,051.80
EBIT		5,242.12		8,203.10		18,275.23		19,389.94		21,789.22		29,489.33		33,601.24
Interest Received		77.43		388.43		350.61		716.61		699.54		687.40		678.62
Interest Paid	-	553.57	-	922.35	-	1,451.27	-	2,999.70	-	2,928.22	-	2,877.41	-	2,840.67
Other Financial income (expense)		571.66	-	333.84		1,135.74		4.74		141.36		159.04		401.42
Profit and Loss Attributable to Associates	_	11.77		8.23		258.63		7.63		7.16		8.06		8.98
EBT		5,325.87		7,343.57		18,568.93		17,119.23		19,709.07		27,466.41		31,849.59
Income Tax	_	562.95	_	904.58	_	2,498.57	-	2,744.85	-	3,160.10	-	4,403.89	-	5,106.68
Net Income		4,762.92		6,438.98		16,070.37		14,374.38		16,548.97		23,062.52		26,742.91

# 7. Balance Sheet

Balance Sheet - Masterplast Nyrt.							
all figures in '000 EUR unless otherwise indicated							
	2019	2020	2021	2022E	2023E	2024E	2025E
Non Current Assets							
PPE	37,193.40	48,904.26	89,624.06	95,897.74	100,692.63	105,727.26	111,013.63
Intangible assets	190.68	176.67	151.19	373.92	392.61	412.24	432.86
Goodwill		4,291.00	-				
Investments in associates	320.84	298.80	553.06	659.38	692.35	726.97	763.31
Deferred tax assets	362.25	753.97	673.89	1,061.60	1,114.68	1,170.42	1,228.94
Total Non-Current Assets	38,067.16	54,424.69	91,002.21	97,992.64	102,892.28	108,036.89	113,438.73
Current Assets							
Inventories	21,256.79	25,084.15	47,088.38	40,826.84	45,460.12	50,677.70	55,745.47
Trade Receivables	14,471.41	16,754.72	21,011.19	28,344.37	32,454.31	36,511.10	40,162.20
Taxes Receivable	784.09	618.57	1,926.17	1.862.97	2.133.10	2,399,74	2,639,71
Other current financial assets	2.33	13.01	74.61	56.81	65.05	73.18	80.50
Other current assets	1,767.43	1,763.58	2,689.14	3,205.69	3,670.51	4,129.33	4,542.26
Cash and Cash Equivalents	4,530.34	33,266.65	15,381.84	46,269.39	43,747.86		46,930.27
Total Current Assets	42,812.39	77,500.68	88,171.33	120,566.07	127,530.95	142,091.30	150,100.42
Total Assets	80,879.55	131,925.37	179,173.53	218,558.72	230,423.23	250,128.19	263,539.15
Equity	,	, , , , , , , , , , , , , , , , , , , ,	,	-,	,	,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Share Capital	5,503,94	5,503,94	5,503,94	5,503.94	5,503,94	5,503,94	5,503,94
Reserves	22,437.94	23,836.62	28,605.65	45,120.59	47,569.97	51,637.98	54,406.63
Redeemed Treasury Shaes			- 2,252.30	- 2,297.34			
Parent Company's Share of the Profit or Loss	4,572,94	5,767.98	15,860,83	12,218.22	14.066.62	19,603,14	22,731.48
Equity Attributable to Parent Company's Shareholders	32,133.38	34,970.12	47,718.12	60,545.41	64,797.24	74,354.91	80,204.08
Non-Controlling Interests	472.96	1,899.18	646.12	5,239.88	5,501.87	5,776.96	6,065.81
Total Equity	32,606.339	36,869,292	48,364.245	65,785.284	70,299.115	80,131.876	86,269.893
Long-Term Liabilities	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	-,	,	,,,,,,,	,	,
Long-Term Loans	3,863.60	3,925.53	4,152.42	4,929.15	5,196.74	5,641.14	5,943.60
Liabilities from Issued Bonds	18,136.17	32,771.80	56,835.59	55,698.88	54,584.90	53,493.20	52,423.34
Deferred Tax Assets	265.72	337.91	502.36	597.47	629.91	683.77	720.43
Deferred Income	3,748.35	3,362.16	29,923.22	20,989.83	20,003.35	19,003.77	18,904.15
Other Long-Term Liabilities	694.77	4,598.55	650.86	8,684.61	8,318.91	8,372.38	8,089.36
Total Non-Current Laibilities	26,708.61	44,995.95	92,064.43	90,899.94	88,733.81	87,194.27	86,080.88
Current Liabilities	.,	,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	,	,,,,,	,
Short-Term Loans	5,852,62	5,913.55	6,063.07	15,796.48	20,526.98	25,606,29	27,155.04
Trade Payables	10,727,78	13,306.27	16,789.73	19,955.41	22,824.93	25,107.61	28,135.81
Short Term Financial Leasing Liabilities	289.98	268.76	299.16	581.55	613.12	665.55	701.23
Other Current Financial Liabilities	92.09	2,479.71	4,299.71	3,985.03	4,201.36	4,560.65	4,805.17
Taxes Payable	1,047.45	2,496.54	3,262.78	6,341.31	7,300.64	10,174.12	11,797.74
Current Part of Deferred Income	625.66	449.80	2,784.96	765.20	876.16	985.68	1,084.24
Provisions	218.82	317.17	567.26	588.38	620.32	673.37	709.47
Other Current Liabilities	2,710.21	24,828.34	4,678.19	13,860.12	14,426.80	15,028.79	16,799.68
Total Current Liabilities	21,564.60	50,060.13	38,744.86	61,873.49	71,390.31	82,802.04	91,188.38
Total Liabilities	48,273.21	95,056.08	130,809.29	152,773.43	160,124.12	169,996.32	177,269.26
Equity and Liabilities	80,879.55	131,925.37	179,173.53	218,558.72	230,423.23	250,128.19	263,539.15

Source: Dr. Kalliwoda Research GmbH © 2021

# 8. Financial Ratios

Fiscal year	2019	2020	2021	2022E	2023E	2024E	2025E
Gross margin	18%	22%	21%	21%	22%	23%	23%
EBITDA margin	7%	9%	12%	11%	11%	13%	13%
EBIT margin	5%	7%	10%	9%	9%	11%	11%
Net margin	5%	6%	10%	8%	8%	10%	10%
Return on equity (ROE)	15%	17%	33%	22%	24%	29%	31%
Return on assets (ROA)	6%	6%	10%	7%	7%	10%	10%
Return on capital employed (ROCE)	8.84%	10.02%	13.01%	12.38%	13.70%	17.62%	19.50%
Net debt (€ '000)	43,742.87	61,789.43	115,427.44	106,504.04	116,376.25	121,696.06	130,338.99
Net gearing	134%	168%	239%	162%	166%	152%	151%
Equity ratio	40%	28%	27%	30%	31%	32%	33%
Current ratio	1.99	1.55	2.28	1.95	1.79	1.72	1.65
Quick ratio	1.00	1.05	1.06	1.29	1.15	1.10	1.03
Net interest cover	11.01	15.36	16.60	8.49	9.78	13.47	15.54
Net debt/EBITDA	5.97	5.58	5.06	4.37	4.23	3.39	3.21
Tangible BVPS	2.45	2.77	3.64	4.93	5.27	6.01	6.48
Capex/Sales	9%	11%	23%	5%	4%	4%	4%
Working capital/Sales	20%	22%	26%	27%	23%	21%	19%
EV/Sales	0.88	1.72	1.38	1.20	1.09	0.99	0.93
EV/EBITDA	12.82	19.05	11.54	10.63	9.79	7.65	6.98
EV/EBIT	17.92	25.72	14.41	13.36	12.35	9.32	8.44
Price/Tangible BVPS	4.54	4.01	3.05	2.25	2.11	1.85	1.72
P/E	0.32	0.32	1.20	0.92	1.06	1.48	1.71
Revenue	107,104.24	122,672.71	191,488.70	216,382.23	247,757.65	278,727.36	306,600.10
Revenue Growth (%)	10%	15%	52%	13%	15%	13%	10%

# 9. Contacts

		Dr. Kalliwoda Research GmbH,			
Primary Research   Fair Value Ana	alysis   International Roadshows	Steinstraße 24, D-64839 Münster, office Frankfurt Arndtstr. 47, 60325 Frankfurt			
		Tel.: 069-97 20 58 53			
Head:	CEFA-Analyst; University of	Sectors: IT, Software, Electricals & Electronics,			
Dr. Norbert Kalliwoda	Frankfurt/Main; PhD in Economics; Dipl	Mechanical Engineering, Logistics, Laser,			
E-Mail: nk@kalliwoda.com	Kfm., DiplHdl.	Technology, Raw Materials			
Lukas Ankelmann	Junior-Analyst; University Nuremberg	Sectors: Technology, New Media, Food & Beverage			
E-Mail: la@kalliwoda.com					
Noah Barnekow	Frankfurt School of Finance &	Sectors: Aviation, Automotive, Technology,			
E-Mail: nb@kalliwoda.com	Management	Sustainability Approach			
Alejandro Cuadros	Junior-Analyst; University of	Sectors: Technology, Video Games, Real Estate			
E-Mail: ac@kalliwoda.com	Frankfurt/Main, Economics				
Leander Gruß	Junior-Analyst (University Rotterdam)	Sectors: eSports, Gaming, Consumer, Retail,			
E-Mail: lg@kalliwoda.com		Fashion			
Giuseppe Inserra	Junior-Analyst (Universita´ degli	Sectors: Gaming Entertainment, Fintech, Financial			
E-Mail: gi@kalliwoda.com	Studi di Catania, Economics)	Markets, Commodities, Real Estate			
Michael John	DiplIng. (Aachen)	Sectors: Chemicals, Chemical Engineering, Basic			
E-Mail: mj@kalliwoda.com		Metals, Renewable Energies, Laser/Physics			
Martin Kostovski	Analyst (Frankfurt School of Finance and	Sectors: Software, Commodities			
E-Mail: mko@kalliwoda.com	Management, BSc. focus on Banking and Finance)				
Witold Konrad Kosinski					
E-Mail: wk@kalliwoda.com					
Sebastian Krawczyk	Bachelor Management, Quant. Meth. in	Sectors: Quantitative Methods, Automotive,			
E-Mail: sk@kalliwoda.com	Economics & Inf. Systems at Warsaw School/Mannheim, CFA Can.	Technology			
Dr. Heinz Müller	Dr. agr, Diplagr. (Agrarökonomie)	Sectors: Agrochemicals, Consumer Chemicals,			
E-Mail: hm@kalliwoda.com		Chemicals			
Vittoria Lou D. Mawis	Architect; University Barcelona	Sectors: Assistant Office & Real Estate Research			
E-Mail: cl@kalliwoda.com					
Dr. Christoph Piechaczek	DiplBiologist; Technical University	Sectors: Biotech & Healthcare; Medical Technology			
E-Mail: cp@kalliwoda.com	Darmstadt; Univ. Witten-Herdecke.	Pharmaceutical			
Nele Rave	Lawyer; Native Speaker, German School	Legal adviser			
E-Mail: nr@kalliwoda.com	London,				

Hellmut Schaarschmidt;	DiplGeophysicists; University of	Sectors: Oil, Regenerative Energies, Specialities
E-Mail: hs@kalliwoda.com	Frankfurt/Main.	Chemicals, Utilities
Dr. Erik Schneider	DiplBiologist; Technical University	Sectors: Biotech & Healthcare; Medical Technology
E-Mail: es@kalliwoda.com	Darmstadt; Univ. Hamburg.	Pharmaceutical
Leonard Schüppler	Junior-Analyst; WHU - Otto Beish. School	Sectors: Luxury Goods, Consumers, digital
E-Mail: ls@kalliwoda.com	of Management Vallendar	businesses.
Hans-Georg Sutter	DiplWirtschaftsingenieur University	Sectors: IT/e-commerce
E-Mail: hsu@kalliwoda.com	Kaiserslautern	
Lukas Thiele	Bachelor Business Administration,	Sector: Automotive, Technology, IT
E-Mail: lt@kalliwoda.com	Univers. Frankfurt am Main	
Also view Sales and Earnings	Analyst of this research:	
Estimates:	Dr. Norbert Kalliwoda, CEFA	
DR. KALLIWODA   RESEARCH on		
Terminals of Bloomberg,		
Thomson Reuters, vwd group and Factset		

### 10. Disclaimer: Material information, disclosures and disclaimers

### A. Material information

Investment in financial instruments and securities (e.g. shares, bonds) is generally associated with high risks. It is possible that the investors lose some or all of the invested money. Potential investors should be aware of the fact that the prices of securities could fall and rise. The income from such an\_investment might be considerable fluctuations. Investment strategies are not appropriate at all times and past results are not a guarantee for the future performance. Investors should make their own and independent decisions as to whether a risky investment.

B. Disclosures according to Section 34b of the German Securities Trading Act (WpHG) and to the German Regulation governing the Analysis of Financial Instruments (FinAnV).

*I. Information about author, company held accountable, regulatory authority:* 

Company responsible for the content of this document: DR. KALLIWODA RESEARCH GmbH, Frankfurt am Main, Germany.

Regulatory authority for DR. KALLIWODA RESEARCH GmbH is the Federal Financial Supervisory Authority (BaFin), Graurheindorfer Straße 108, 53117 Bonn, Germany and Lurgiallee 12, 60439 Frankfurt am Main, Germany.

Author of this research: Dr. Norbert Kalliwoda, Analyst, CEO and founder of DR. KALLIWODA RESEARCH GmbH.

### II. Additional Information:

### 1. Sources of information:

Essential sources of information for the compilation of this document are publications from domestic and international information services and media (e.g. Bloomberg, dpa-AFX, Reuters, VWD, among others), financial press (e.g. Allgemeine Zeitung Frankfurter, Börsenzeitung, Financial Times Handelsblatt and others), specialized trade press, published statistics, rating agencies as well as publications by peer group companies and the company itself. Additionally, conservation has been held with the management of the company. This document was made available to the company before publishing to ensure the correctness of the information provided.

2. Summary of the basis of valuation principles and methods used to prepare this document:

Within the scope of the evaluation of companies the following valuation methods are applied: Multiple-based models (Price/Earnings, Price/Cash-flow, Price/Book value, EV/Sales, EV/EBIT, EV/EBITDA), peer group comparisons, historic valuation methods, discounting models, sum-of-the-parts-approaches, substance-valuation methods and swot-analyses. The valuation principles and models are dependent on macroeconomic factors, such as interest rates, exchange rates, raw materials and on basic assumptions about the economy. Besides, the market moods and market sentiment affect the valuation of enterprises. The approaches are based on expectations that could change rapidly and without advance warning according on developments specific to individual branch. The valuation results and fair values derived from the models might therefore change accordingly. The ratings are the evaluation results and refer to a fair value pricing reflecting a time-horizon of up general relate to a twelve-months. Nevertheless, evaluation results are subject to changing market conditions and constitute merely a snapshot. The evaluation results and fair values may be reached faster or slower than expected by the analysts. The results and fair values may to be scale upwards or downwards.

DR. KALLIWODA RESEARCH GmbH uses the following rating model:

	LESET MET OHIOTI uses the following fating model.			
BUY:	Based on our analysis, we expect the stock to appreciate and produce a total return of at least 10% over the netwelve months			
ACCUMULATE:	Based on our analysis, we expect the stock to appreciate and produce a total return between 5% - 10% over the next twelve months			
HOLD:	Based on our analysis, we expect the stock to produce a total return between -5% and +5% over the next twelve months			
REDUCE:	Based on our analysis, we expect the stock to cause a negative return between -5% and -10% over the next twelve months			
SELL:	Based on our analysis, we expect the stock to cause a negative return exceeding -10% over the next twelve months			

For the sustainability ranking DR. KALLIWODA RESEARCH GmbH uses the 17 United Nations Sustainable Development Goals, where each goal is classified as follows:

-1	The company negatively contributes to the goal.
0	The company does not contribute to the goal at all.
1	The company positively contributes to the goal.
2	The company profoundly contributes to the goal.
3	The company significantly contributes to the goal.

From adding up the given numbers, it is being set in a ratio to the maximum points (e.g. 51). The following model shows the note procurement:

A =5 Trees	100% - 76%	The company exceptionally contributes to the goal.
B = 4 Trees	75% - 51%	The company promotes the transition to sustainability.
C = 3 Trees	50% - 26%	The company is on the way to sustainability.
D = 2 Trees	25% - 0%	The company minimizes its negative impact.
E = 1 Tree	< 0%	The company is not sustainable.

Date of first publication of this document: 9th of September 2022.

# 4. Updates:

A specific update of this document has currently not been set. The research reflects the author's judgement on the date of this publication and is subject to change without any notice. The document might be incomplete or reduced and it may not contain all information concerning the company covered. It is in the sole decision of DR. KALLIWODA RESEARCH GmbH whether and when a potential update of this research is made.

# III. Disclosures about potential conflicts of interest:

The business model of DR. KALLIWODA RESEARCH GmbH is based on economic relationships with issuer company and equity transactions to be performed relating to the issuer's stock. Dr. Kalliwoda Research has entered into an agreement about the creation of this document with the company which is, or whose financial instruments are the issue of this research.

Conflicts of interest may be in existence with employees of DR. KALLIWODA RESEARCH GmbH who are the authors of this document as well as other persons that were involved in the preparation of this research or related parties.

Following conflicts of interest might exist:

- 1. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties are possibly holders of instruments that are mentioned in this research (or that are linked to these instruments) or might become holders and could regularly trade the emitter's securities or securities based on these issues as principal or agent.
- 2. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties could have participated in leading a consortium for the emitter via a public offering of the financial instruments that are the subject of this research.
- 3. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties might have been party to an agreement on the provision of investment banking services with the emitter which is the subject of this research, or have received services or a pledge to perform under the terms of such an arrangement during the same period.
- 4. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties may have other substantial economic interests concerning to the emitter which is the subject of this research.
- 5. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties might have been party to an agreement with the company, which is the subject of this research, resulting in receiving the compensation for preparation of this research.
- 6. DR. KALLIWODA RESEARCH GmbH employees or other persons that were involved in the preparation of this document or related parties received the feedback concerning the company profile and SWOT from the company, which is the subject of this research, before publishing this report to the public.

Important: Please get familiar with possible risks and possible conflicts of interest in the disclosure and disclaimer at the end of this report, especially for this report: 6. and 7.

The analysts have limited access to gain information that possibly could constitute a conflict of interest for the institution DR. KALLIWODA RESEARCH GmbH keeps insider registers appropriate to sec. 15 WpHG for assignees that normally have approach to inside information. Insiders' dealings appropriate to sec. 14 WpHG categorically are prohibited.

The analysts that composed this research did not receive or acquire shares in the emitter that is the subject of this document at any time. The analysts mentioned above herby certify that all of the views expressed accurately reflect the individual views about the emitter. No part of the indemnity was, is or will be, directly or indirectly, linked to the evaluation result or views expressed by the analyst in this research.

### C. Disclaimer:

This document is published and being distributed by DR. KALLIWODA RESEARCH GmbH solely for informational purposes and for the personal use by persons in Germany. This research is not intended to be in any form an offer or advice to buy or sell the securities referred to herein. This research is intended to provide information to assist investors in making their own investment decisions. Any decision to purchase any securities of the emitter must be made solely on the basis of the information contained in the offering documents from the emitter relating to such securities and not on the contents hereof. Furthermore, our recommendation may not be fully suitable to every investor, depending on their investment objective, individual financial situation or targeted holding period.

Potential investors should seek professional and individual information and advice before making their investment decisions. This document neither constitutes a contract or any kind of obligation.

Neither this document nor any copy, in whole or in part, thereof may be distributed in any other jurisdiction where its distribution might be restricted by law, and person into whose published this document comes should inform and observe themselves about any such restrictions.

The information within this document has been obtained from sources believed by DR. KALLIWODA RESEARCH GmbH to be reliable. DR. KALLIWODA RESEARCH GmbH does not examine the information to be verify and complete, nor warrantees its correctness and completeness. Although due attention has been taken in compilation this document, it cannot be excluded that the information given is not complete or the document contains mistakes.

The liability of DR. KALLIWODA RESEARCH GmbH shall be restricted to gross negligence and willful misconduct. All aspects penned in this document are those of DR. KALLIWODA RESEARCH GmbH respectively the authors and subject to modify without notice. Possible faults or incompleteness of this document may be reformed by DR. KALLIWODA RESEARCH GmbH and do not constitute reasons for liability, neither with regard to indirect nor to direct or consequential losses.

Moreover, DR. KALLIWODA RESEARCH GmbH does not accept any responsibility and liability for any damage arising from using of this research or its contents or otherwise arising in relation herewith. In each case, the liability and responsibility of DR. KALLIWODA RESEARCH GmbH is limited to typical, predictable damages and the liability for any direct or indirect losses is excluded.

This document is subject to the laws of the Federal Republic of Germany. Place of jurisdiction is Frankfurt am Main, Germany.

This document or any copy, in whole or in part thereof, may not be distributed in any other jurisdiction where its distribution might be restricted by law and persons who have access to this document have to inform and observe themselves about any such restrictions.

In the United Kingdom this document is to be distributed only to persons who are described in Section 11 (3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1996 (as amended). This research may not be distributed and forwarded directly or indirectly to any other group of individuals. The distribution of this document in other international jurisdictions may be restricted by law and individuals who possess this study should inform themselves of any existing restrictions and comply with them.

Neither this document nor any copy of it may be taken or transmitted into the United States of America, Canada, Japan or Australia or distributed, directly or indirectly, in the United States of America, Canada, Japan or Australia or to any resident thereof. Any Failure to comply with these restrictions may constitute a violation of United States, Canadian, Japanese or Australian securities laws or the law of any other jurisdiction.

By confirming this document, the reader or user agrees and accepts to be bound by all of the foregoing provisions and this disclaimer. Besides, the user accepts not to distribute this document to unauthorized persons. The user of this document compensated DR. KALLIWODA RESEARCH GmbH for any disadvantages, damages, claims and losses resulting from or in relation with the unauthorized use of this document.

© 2022 DR. KALLIWODA RESEARCH GmbH, Arndtstraße 47, D-60325 Frankfurt am Main. All rights reserved.